Details
| Product Infomation | |
|---|---|
| Product Description: | Homologous Recombination Repair (HRR) is one of the important repair modalities for DNA double-strand damage, and the HRR pathway contains the BRCA1/2 gene. Tumor cells with Homologous Recombination Deficiency (HRD) are sensitive to platinum-containing chemotherapy and Poly ADP-ribose Polymerase inhibitor (PARPi). Currently, PARPi is used in clinical trials for HRD-positive ovarian cancer, the development of IVD concomitant diagnostic products or the screening of concomitant diagnostic products for drug clinical trials, and there is a demand for Reference products. CD HRD-9-N gDNA Reference is derived from paired tumor cell lines and use WGS data to evaluate the HRD reference values of References, which can meet the application needs of IVD companies' reference products, negative reference products in kits, kit performance verification, daily quality control and inter-room quality assessment in the IVD market. |
| Features: | LOH:6 TAI:26 LST:20 HRD Reference (GW)*HRD-sum:52 |
| Method: | Quality Control Method: Digital PCR and others |
| Concentration: | 30 ng/µL |
| Application: | •Evaluate the stability of experimental and analytical processes. •Check whether each independent mutation of LOH, LST and TAI related to HRD can be accurately determined. •Compare WGS data with HRD panel to check Panel design. •Different mixing ratios of tumor and wild type can be used to determine the detection limit of each mutation and determine the minimum tumor ratio. •Negative reference/quality control. |
| Storage: | Store at 2-8℃, 24 months. |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×
